Repligen CEO Tony Hunt leaves post

  • After around nine years in the position
  • Accolades, praise and thanks for Hunt
  • Olivier Loeillot taking over
  • Hunt will remain as Executive Chair at Repligen
  • Hunt said 88 words

(exechange) — Waltham, Massachusetts, June 13, 2024 — Tony Hunt, chief executive of Repligen, leaves his position. As announced by Repligen Corp. in a news release and in a regulatory filing published on Thursday, June 13, 2024, Tony J. Hunt leaves his post as chief executive officer at the life sciences company, after around nine years in the role, effective September 1, 2024.

Tony Hunt’s duties as CEO will be taken over by Olivier Loeillot, currently President and Chief Commercial Officer at Repligen Corp.

Hunt will remain as Executive Chair at Repligen

Repligen stated: “Repligen Corporation …, a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors … has approved the planned transition of Tony J. Hunt from Chief Executive Officer … to Executive Chair, effective September 1, 2024.”

Share price decline since June 2021

The announcement follows a decline in Repligen Corp.’s share price of 17% since June 2021.

In the position of CEO since 2015

Tony Hunt became CEO of the Company in 2015.

Tony J. Hunt was named President and Chief Executive Officer (“CEO”) and has served on the Board since May 2015.

He currently serves as CEO after relinquishing his role as President in October 2023.

He joined Repligen in May 2014 as Chief Operating Officer (“COO”), overseeing commercial and manufacturing operations.

Before coming to Repligen, Hunt was President of Bioproduction at Life Technologies Corporation, a global life sciences company which was acquired by Thermo Fisher Scientific (“Thermo Fisher”) in 2014.

He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011.

From 2000 to 2008, Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies.

Hunt also serves on the board of directors of one publicly traded company, 908 Devices Inc.

Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and a M.B.A. from Boston University School of Management.

88 words by Tony Hunt

In the release announcing his departure as CEO of Repligen Corp., Tony Hunt received accolades, praise and thanks.

In the release announcing his departure as CEO, Tony Hunt said 88 words.

“Excellent choice”

Tony Hunt stated: “It has been my privilege to lead Repligen for over nine years and execute on the vision we set to bring disruptive, high value bioprocessing technologies to market. Having known and respected Olivier for many years – and now having worked directly with him over the past months – I share the Board’s confidence that Olivier is an excellent choice for the CEO role and for the future of Repligen. As Executive Chair, I look forward to working with Olivier and focusing on corporate strategy, new product and business opportunities.”

The above text is an excerpt from the exechange report 25.2024 ($), publication date June 17, 2024.